Merck & Co. Inc.'s PD-1 inhibitor Keytruda has failed to show a survival benefit in the KEYNOTE-040 study of head and neck cancer, which was meant to confirm an accelerated approval, but the company does not foresee a labeling change.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?